My watch list

Nateglinide


Nateglinide
Systematic (IUPAC) name
3-phenyl-2-(4-propan-2-ylcyclohexyl) carbonylamino-propanoic acid
Identifiers
CAS number	105816-04-4
ATC code	A10BX03
PubChem	60026
DrugBank	APRD00593
Chemical data
Formula	C₁₉H₂₇NO₃
Mol. mass	317.423 g/mol
Pharmacokinetic data
Bioavailability	?
Protein binding	98%
Metabolism	?
Half life	1.5 hours
Excretion	?
Therapeutic considerations
Licence data	EU US
Pregnancy cat.	?
Legal status
Routes	?

Nateglinide (INN, trade name Starlix) is a drug for the treatment of type 2 diabetes. Nateglinide was developed by the Swiss pharmaceutical company Novartis.

Additional recommended knowledge

Safe Weighing Range Ensures Accurate Results

Daily Visual Balance Check

How to ensure accurate weighing results every day?

Nateglinide belongs to the meglitinide class of blood glucose-lowering drugs.

Pharmacology

Nateglinide lowers blood glucose by stimulating the release of insulin from the pancreas. It achieves this by closing ATP-dependent potassium channels in the membrane of the β cells. This depolarizes the β cells and causes voltage-gated calcium channels to open. The resulting calcium influx induces fusion of insulin-containing vesicles with the cell membrane, and insulin secretion occurs.

Dosage

Nateglinide is delivered in 60mg & 120mg tablet form.

v • d • e Oral antidiabetic drugs and Insulin analogs (A10)
Biguanides	Metformin
Sulfonylureas	Chlorpropamide, Glibenclamide (Glyburide), Gliclazide, Glimepiride, Glipizide, Gliquidone, Tolazamide, Tolbutamide
Alpha-glucosidase inhibitors	Acarbose, Miglitol, Voglibose
Thiazolidinediones (TZD)	Pioglitazone, Rosiglitazone, Troglitazone
Meglitinides	Nateglinide, Repaglinide, Mitiglinide
Dipeptidyl peptidase-4 (DPP-4) inhibitors	Saxagliptin, Sitagliptin, Vildagliptin
Glucagon-like peptide-1 analog	Exenatide
Insulin analogs	fast acting (Insulin lispro, Insulin aspart, Insulin glulisine), intermediate-acting (NPH insulin), long acting (Insulin glargine, Insulin detemir)